直通进博会 | 进博首秀即双签约！维昇药业携手东富龙、临港新片区共筑生物医药生态

Core Insights - Weisheng Pharmaceutical made its debut as an exhibitor at the China International Import Expo, signing two significant agreements focused on strategic cooperation in dual-chamber freeze-dried formulation technology and industrial collaboration with local authorities [1][6]. Group 1: Strategic Partnerships - The collaboration with Dongfulong aims to address the industry pain points of stability and ease of use in high-end biological formulations through dual-chamber freeze-dried technology [2][5]. - Weisheng's core product, Lonapegsomatropin, will utilize this technology, allowing for stable storage at room temperature for up to six months without preservatives [2][3]. Group 2: Product Development and Market Entry - The application for Lonapegsomatropin's market approval is expected to be accepted by the National Medical Products Administration in March 2024, with a projected approval by the end of 2025 [3]. - The partnership with Dongfulong is intended to ensure quality control throughout the entire process from research and development to commercialization [3][5]. Group 3: Local Development and Ecosystem - Weisheng Pharmaceutical is recognized as a key innovative biopharmaceutical company in the Lingang New Area, focusing on endocrine-related treatments and has rapidly grown since its establishment in 2022 [6]. - The agreements with the Lingang New Area Management Committee and Lingang Group aim to deepen industrial collaboration and enhance the local ecosystem for biopharmaceuticals [6][9].